{"id":348270,"date":"2019-03-28T05:05:03","date_gmt":"2019-03-28T05:05:03","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=348270"},"modified":"2019-03-28T05:05:03","modified_gmt":"2019-03-28T05:05:03","slug":"alzheimers-disease-therapeutics-and-diagnostics-market-2019-global-trend-segmentation-and-opportunities-forecast-to-2024","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-therapeutics-and-diagnostics-market-2019-global-trend-segmentation-and-opportunities-forecast-to-2024_348270.html","title":{"rendered":"Alzheimer\u2019s Disease Therapeutics and Diagnostics Market 2019 Global Trend, Segmentation And Opportunities Forecast To 2024"},"content":{"rendered":"
\n
“Alzheimer\u2019s Disease Therapeutics and Diagnostics”<\/div>\n<\/div>\n
Wiseguyreports.Com Adds \u201cAlzheimer\u2019s Disease Therapeutics and Diagnostics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024\u201d To Its Research Database<\/p>\n<\/div>\n

Alzheimer’s Disease Therapeutics and Diagnostics <\/strong>Industry<\/strong><\/a><\/p>\n

Description<\/strong><\/p>\n

Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer’s disease. One in nine people aged 65 and above has Alzheimer’s disease. By 2050, the number of people aged 65 and above affected with Alzheimer’s disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.<\/p>\n

Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.<\/p>\n

The global Alzheimer’s Disease Therapeutics and Diagnostics market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. <\/p>\n

This report focuses on Alzheimer’s Disease Therapeutics and Diagnostics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alzheimer’s Disease Therapeutics and Diagnostics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. <\/p>\n

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.<\/p>\n

Request for Sample Report @ https:\/\/www.wiseguyreports.com\/sample-request\/3871191-global-alzheimer-s-disease-therapeutics-and-diagnostics-market<\/a> <\/strong><\/p>\n

The following manufacturers are covered: <\/p>\n

Namenda <\/strong>
Aricept <\/strong>
Exelon <\/strong>
Solanezumab <\/strong>
Gantenerumab <\/strong>
Verubecestat <\/strong>
Pfizer <\/strong>
Eisai <\/strong>
Actavis <\/strong>
Lundbeck <\/strong>
Daiichi Sankyo <\/strong>
Novartis <\/strong>
TauRx<\/strong><\/p>\n

Segment by Regions <\/strong>
North America 
Europe 
China 
Japan<\/p>\n

Segment by Type <\/strong>
Biomarkers 
Cholinesterase inhibitors 
NMDA receptor antagonists 
Brain imaging 
Blood tests<\/p>\n

Segment by Application <\/strong>
Drugs Market 
Diagnostics Market<\/p>\n

Leave a Query @ https:\/\/www.wiseguyreports.com\/enquiry\/3871191-global-alzheimer-s-disease-therapeutics-and-diagnostics-market<\/a><\/strong><\/p>\n

 <\/p>\n

Table of Contents (Some Major Key players & points)<\/strong><\/p>\n

7 Company Profiles and Key Figures in Alzheimer’s Disease Therapeutics and Diagnostics Business 
7.1 Namenda 
7.1.1 Namenda Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.1.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.1.3 Namenda Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.1.4 Main Business and Markets Served 
7.2 Aricept 
7.2.1 Aricept Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.2.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.2.3 Aricept Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.2.4 Main Business and Markets Served 
7.3 Exelon 
7.3.1 Exelon Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.3.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.3.3 Exelon Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.3.4 Main Business and Markets Served 
7.4 Solanezumab 
7.4.1 Solanezumab Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.4.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.4.3 Solanezumab Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.4.4 Main Business and Markets Served 
7.5 Gantenerumab 
7.5.1 Gantenerumab Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.5.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.5.3 Gantenerumab Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.5.4 Main Business and Markets Served 
7.6 Verubecestat 
7.6.1 Verubecestat Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.6.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.6.3 Verubecestat Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.6.4 Main Business and Markets Served 
7.7 Pfizer 
7.7.1 Pfizer Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.7.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.7.3 Pfizer Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.7.4 Main Business and Markets Served 
7.8 Eisai 
7.8.1 Eisai Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.8.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.8.3 Eisai Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.8.4 Main Business and Markets Served 
7.9 Actavis 
7.9.1 Actavis Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.9.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.9.3 Actavis Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.9.4 Main Business and Markets Served 
7.10 Lundbeck 
7.10.1 Lundbeck Alzheimer’s Disease Therapeutics and Diagnostics Production Sites and Area Served 
7.10.2 Alzheimer’s Disease Therapeutics and Diagnostics Product Introduction, Application and Specification 
7.10.3 Lundbeck Alzheimer’s Disease Therapeutics and Diagnostics Production, Revenue, Price and Gross Margin (2014-2019) 
7.10.4 Main Business and Markets Served 
7.11 Daiichi Sankyo 
7.12 Novartis 
7.13 TauRx<\/p>\n

Buy Now @ https:\/\/www.wiseguyreports.com\/checkout?currency=one_user-USD&report_id=3871191<\/a> <\/strong><\/p>\n

Continued…                        <\/strong><\/p>\n

 <\/strong><\/p>\n

Contact Us: <\/strong>Sales@Wiseguyreports.Com<\/strong><\/a> Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com<\/a>
Contact Person:<\/strong> Norah Trent
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> https:\/\/www.wiseguyreports.com\/sample-request\/3871191-global-alzheimer-s-disease-therapeutics-and-diagnostics-market<\/a><\/p>\n

 <\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Alzheimer\u2019s Disease Therapeutics and Diagnostics” Wiseguyreports.Com Adds \u201cAlzheimer\u2019s Disease Therapeutics and Diagnostics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024\u201d To Its Research Database Alzheimer’s Disease Therapeutics and Diagnostics Industry Description Alzheimer’s disease (AD) is … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-348270","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/348270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=348270"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/348270\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=348270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=348270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=348270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}